leisure time -WSS

leisure time

author：comprehensive 2025-09-03 15:20:19 - browse：3478

Venture capital firm RA Capital is starting a new incubator, setting the stage for the firm to create new startups over the next several years that hone in on synthetic biology, a long-gestating field that insiders say is getting renewed interest.

The Boston-based VC’s incubator is called RASyn, and will be led by Robert Nicol, according to people familiar with the firm’s plans. Nicol spent more than 20 years at the Broad Institute, where he co-founded the MIT-Broad Foundry for Synthetic Biology, as well as HiFiBio Therapeutics and Design Pharmaceuticals.

RA Capital confirmed RASyn’s existence. Senior Managing Director Josh Resnick told STAT it’s part of the firm’s work to rethink how it develops platforms — core technologies or scientific approaches that underpin all of the drugs a biotech develops — but declined to comment further.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Cancer drug shortages should be causing more outrage
Next article： Biotech lab space demand falls sharply

WSS

Drug for rare kidney disease narrowly misses mark in clinical trial

Thermo Fisher plant for manufacturing gene therapies to expand

Scientists boost immune system in aging mice by making it youthful

Intarcia’s device

The Readout: Lenmeldy, GLP

Ukraine and a new approach to mental health in war

hotspot

leisure time

focus

Anesthesiologist group: stop taking Ozempic before surgery

Vertex Pharmaceuticals may move headquarters in Boston

Heart attack and stroke risk calculators need revising

Hearing on Medicare drug price negotiation gets unusually heated

DIEP, the 'gold standard' of breast reconstruction, is under threat

Why the world’s most expensive drug might be worth the price

Jerome Adams on the need for new antivirals for Covid

Food as medicine: Medically tailored meals may get standardized

Medical records are filled with copy

Emergency workers more likely to restrain Black patients: study

focus

Abortion pill case raises question: who can sue the FDA?

CDC's new outbreak response network to include Northeastern

Merck drug for rare lung condition set for approval in U.S.

Biotech lab space demand falls sharply

Decaf coffee targeted by food safety group under obscure FDA rule

Primary care physicians play key roles in Alzheimer's management

hotspot

entertainment

leisure time

Wikipedia